The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10735 malaria professionals are enjoying the free benefits of MalariaWorld today

dihydropteroate synthetase

Genetic diversity of the Plasmodium falciparum GTP-cyclohydrolase 1, dihydrofolate reductase and dihydropteroate synthetase genes reveals new insights into sulfadoxine-pyrimethamine antimalarial drug resistance

January 6, 2021 - 13:10 -- Open Access
Author(s): 
Turkiewicz A, Manko E, Sutherland CJ, Diez Benavente E, Campino S, Clark TG
Reference: 
PLoS Genet. 2020 Dec 31;16(12):e1009268

Plasmodium falciparum parasites resistant to antimalarial treatments have hindered malaria disease control. Sulfadoxine-pyrimethamine (SP) was used globally as a first-line treatment for malaria after wide-spread resistance to chloroquine emerged and, although replaced by artemisinin combinations, is currently used as intermittent preventive treatment of malaria in pregnancy and in young children as part of seasonal malaria chemoprophylaxis in sub-Saharan Africa. The emergence of SP-resistant parasites has been predominantly driven by cumulative build-up of mutations in the dihydrofolate reductase (pfdhfr) and dihydropteroate synthetase (pfdhps) genes, but additional amplifications in the folate pathway rate-limiting pfgch1 gene and promoter, have recently been described.

Subscribe to RSS - dihydropteroate synthetase